News Mundipharma to market Herceptin biosimilar in key EU markets Mundipharma's third biosimilar tie-up with Celltrion
News Its Herceptin biosimilar nearing launch, Celltrion begins wo... South Korea’s Celltrion has started work on a biosimilar version of pembrolizumab, Merck & Co’s blockbuster immunotherapy Keytruda.
News Pfizer's rituximab biosimilar gets late-stage trial boost Phase 3 success sets up showdown with Roche, Sandoz, and Celltrion
News Roche's Herceptin facing further biosimilar threats in US Breast cancer blockbuster facing potential trio of US competitors.
News Celltrion's rituximab biosimilar could have four names in EU Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands.
Market Access Policy in focus: Trump’s Most Favoured Nations drug pricing ... Alice Valder Curran, a partner at Hogan Lovells, provides an update on what's happening right now with Most Favoured Nations drug pricing.
Sales & Marketing FH25: Individual centric investing with Steve Seuntjens In a new FH25 podcast episode, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital.
